COBALT: Coversin Global Study: An Open-Label, Safety and Efficacy Trial in PNH Patients

Trial Profile

COBALT: Coversin Global Study: An Open-Label, Safety and Efficacy Trial in PNH Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Coversin (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms COBALT
  • Sponsors Akari Therapeutics
  • Most Recent Events

    • 08 Dec 2017 Results published in the Akari Therapeutics media release.
    • 08 Dec 2017 Primary endpoint of Reduction in serum LDH to less than or equal to 1.8 times the upper limit of normal has been met, according to an Akari Therapeutics media release.
    • 04 Dec 2017 According to an Akari Therapeutics media release, data of this trial will be presented at an event being held at the Omni Atlanta Hotel at CNN Center on Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top